

Supplementary material 5: Effect on Cardiovascular Outcomes Compared to Non-Placebo, Non-Insulin interventions

Outcomes	Number of Studies	Risk Ratio (95% Confidence Interval)	I ²	Cochran Q	p-value
<i>Comparison to Sulfonylurea¹</i>					
Total MI	1	0.70 (0.40 to 1.21)	-	-	0.20
MACE	1	0.81 (0.56 to 1.17)	-	-	0.26
Stroke	1	1.18 (0.61 to 2.28)	-	-	0.62
Coronary Revascularization	1	0.55 (0.36 to 0.83)	-	-	<0.01*
Cardiovascular Mortality	1	0.56 (0.25 to 1.26)	-	-	0.16
Heart Failure	1	0.46 (0.25 to 0.87)	-	-	0.02*
Unstable Angina	1	0.58 (0.23 to 1.47)	-	-	0.25
<i>Comparison to DPP4-I²</i>					
Total MI ^{1,2}	2	0.62 (0.09 to 4.11)	0.00%	0.58	0.19
Non-fatal MI	1	1.50 (0.61 to 36.59)	-	-	-
MACE	1	0.70 (0.49 to 1.00)	-	-	0.05
Stroke	1	1.06 (0.56 to 2.01)	-	-	0.86
Coronary Revascularization	1	0.56 (0.37 to 0.85)	-	-	<0.01*

Cardiovascular Mortality	1	0.43 (0.20 to 0.94)	-	-	0.03*
Heart Failure	1	0.47 (0.25 to 0.88)	-	-	0.02*
Unstable Angina	1	0.47 (0.19 to 1.45)	-	-	0.10

Comparison to SGLT2-I³

Total MI	1	1.10 (0.07 to 17.39)			0.95
----------	---	----------------------	--	--	------

Bolded P value ≤0.05 denotes statistical significance

Legend: MI, Myocardial Infarction; MACE, Major Adverse Cardiovascular Events; DPP4-I, Dipeptidyl Peptidase 4 Inhibitor; SGLT2-I, Sodium-Glucose Transport Protein 2 Inhibitor;

References

1. Green JB, Everett BM, Ghosh A, et al. Cardiovascular outcomes in GRADE (Glycemia reduction approaches in type 2 diabetes: A comparative effectiveness study). *Circulation*. 2024;149(13):993-1003.
2. Seino Y, Terauchi Y, Osonoi T, et al. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. *Diabetes, obesity and metabolism*. 2018;20(2):378-388.
3. Jabbour SA, Frias JP, Hardy E, et al. Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52-week results of the DURATION-8 randomized controlled trial. *Diabetes care*. 2018;41(10):2136-2146.